PURPOSE: Hedgehog (Hh) pathway signaling has been implicated in prostate cancer tumorigenesis and metastatic development and may be upregulated even further in the castration-resistant state. We hypothesized that antagonism of the Hh pathway with vismodegib in men with metastatic castration-resistant prostate cancer (mCRPC) would result in pathway engagement, inhibition and perhaps induce measurable clinical responses in patients. METHODS: This is a single-arm study of oral daily vismodegib in men with mCRPC. All patients were required to have biopsies of the tumor and skin (a surrogate tissue) at baseline and after 4 weeks of therapy. Ten patients were planned for enrollment. The primary outcome was the pharmacodynamic assessment of Gli1 mRNA suppression with vismodegib in tumor tissue. Secondary outcomes included PSA response rates, progression-free survival (PFS), overall survival (OS) and safety. RESULTS: Nine patients were enrolled. Gli1 mRNA was significantly suppressed by vismodegib in both tumor tissue (4/7 evaluable biopsies, 57%) and benign skin biopsies (6/8 evaluable biopsies, 75%). The median number of treatment cycles completed was three, with a median PFS of 1.9 months (95% CI 1.3, NA), and a median OS of 7.04 months (95% CI 3.4, NA). No patient achieved a PSA reduction or a measurable tumor response. Safety data were consistent with the known toxicities of vismodegib. CONCLUSIONS: Hh signaling, as measured by Gli1 mRNA expression in mCRPC tissues, was suppressed with vismodegib in the majority of patients. Despite this pharmacodynamic response that indicated target inhibition in some patients, there was no apparent signal of clinical activity. Vismodegib will not be developed further as monotherapy in mCRPC.
PURPOSE: Hedgehog (Hh) pathway signaling has been implicated in prostate cancer tumorigenesis and metastatic development and may be upregulated even further in the castration-resistant state. We hypothesized that antagonism of the Hh pathway with vismodegib in men with metastatic castration-resistant prostate cancer (mCRPC) would result in pathway engagement, inhibition and perhaps induce measurable clinical responses in patients. METHODS: This is a single-arm study of oral daily vismodegib in men with mCRPC. All patients were required to have biopsies of the tumor and skin (a surrogate tissue) at baseline and after 4 weeks of therapy. Ten patients were planned for enrollment. The primary outcome was the pharmacodynamic assessment of Gli1 mRNA suppression with vismodegib in tumor tissue. Secondary outcomes included PSA response rates, progression-free survival (PFS), overall survival (OS) and safety. RESULTS: Nine patients were enrolled. Gli1 mRNA was significantly suppressed by vismodegib in both tumor tissue (4/7 evaluable biopsies, 57%) and benign skin biopsies (6/8 evaluable biopsies, 75%). The median number of treatment cycles completed was three, with a median PFS of 1.9 months (95% CI 1.3, NA), and a median OS of 7.04 months (95% CI 3.4, NA). No patient achieved a PSA reduction or a measurable tumor response. Safety data were consistent with the known toxicities of vismodegib. CONCLUSIONS: Hh signaling, as measured by Gli1 mRNA expression in mCRPC tissues, was suppressed with vismodegib in the majority of patients. Despite this pharmacodynamic response that indicated target inhibition in some patients, there was no apparent signal of clinical activity. Vismodegib will not be developed further as monotherapy in mCRPC.
Authors: James Kim; Jean Y Tang; Ruoyu Gong; Jynho Kim; John J Lee; Karl V Clemons; Curtis R Chong; Kris S Chang; Mark Fereshteh; Dale Gardner; Tannishtha Reya; Jun O Liu; Ervin H Epstein; David A Stevens; Philip A Beachy Journal: Cancer Cell Date: 2010-04-13 Impact factor: 31.743
Authors: Eleni Efstathiou; Maria Karlou; Sijin Wen; Anh Hoang; Curtis A Pettaway; Louis L Pisters; Sankar Maity; Patricia Troncoso; Christopher J Logothetis Journal: Prostate Date: 2012-07-02 Impact factor: 4.104
Authors: Emmanuel S Antonarakis; Elisabeth I Heath; David C Smith; Dana Rathkopf; Amanda L Blackford; Daniel C Danila; Serina King; Anja Frost; A Seun Ajiboye; Ming Zhao; Janet Mendonca; Sushant K Kachhap; Michelle A Rudek; Michael A Carducci Journal: Oncologist Date: 2013-01-22
Authors: Sunil S Karhadkar; G Steven Bova; Nadia Abdallah; Surajit Dhara; Dale Gardner; Anirban Maitra; John T Isaacs; David M Berman; Philip A Beachy Journal: Nature Date: 2004-09-12 Impact factor: 49.962
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Mengqian Chen; Matthew Tanner; Alice C Levine; Elina Levina; Patrice Ohouo; Ralph Buttyan Journal: Cell Cycle Date: 2009-01-01 Impact factor: 4.534
Authors: Greg Shaw; Anna M Price; Elena Ktori; Isabelle Bisson; Patricia E Purkis; Siobhan McFaul; R Tim D Oliver; David M Prowse Journal: Eur Urol Date: 2008-02-04 Impact factor: 20.096
Authors: Michael C Haffner; Gunes Guner; Diana Taheri; George J Netto; Doreen N Palsgrove; Qizhi Zheng; Liana Benevides Guedes; Kunhwa Kim; Harrison Tsai; David M Esopi; Tamara L Lotan; Rajni Sharma; Alan K Meeker; Arul M Chinnaiyan; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Rohit Mehra; Emmanuel S Antonarakis; Charles G Drake; Angelo M De Marzo Journal: Am J Pathol Date: 2018-03-22 Impact factor: 4.307
Authors: Alessandra V de S Faria; Adamu Ishaku Akyala; Kaushal Parikh; Lois W Brüggemann; C Arnold Spek; Wanlu Cao; Marco J Bruno; Maarten F Bijlsma; Gwenny M Fuhler; Maikel P Peppelenbosch Journal: J Biol Chem Date: 2019-04-16 Impact factor: 5.157
Authors: Ashley E Ross; Robert M Hughes; Stephanie Glavaris; Kamyar Ghabili; Ping He; Nicole M Anders; Rana Harb; Jeffrey J Tosoian; Luigi Marchionni; Edward M Schaeffer; Alan W Partin; Mohamad E Allaf; Trinity J Bivalacqua; Carolyn Chapman; Tanya O'Neal; Angelo M DeMarzo; Paula J Hurley; Michelle A Rudek; Emmanuel S Antonarakis Journal: Oncotarget Date: 2017-10-26